Literature DB >> 20544528

Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase.

G J Peters1, J Hodzic, B Ortega, E Giovannetti, A D Adema, R Broekhuizen, G J Kaspers, I Hubeek.   

Abstract

Deoxycytidine kinase (dCK) is essential for phosphorylation of natural deoxynucleosides and analogs, such as gemcitabine and cytarabine, two widely used anticancer compounds. We hypothesized that DNA methylation of SP1 binding sites in the dCK promoter region might affect dCK expression. Using methylation specific PCR (MSP), methylation was detected in one of the SP1 binding sites of the dCK promoter, in most tested cancer cell lines and in patient samples from brain tumors and leukemia. This SP1 site is a 3'GC box, which upon hypomethylation negatively regulates dCK mRNA expression. In conclusion, we developed a new MSP method showing methylation of the 3' GC-box in the dCK promoter region in tumor cells and patient samples. Methylation might therefore regulate transcription of dCK, and should be studied further to understand its role in influencing gemcitabine and cytarabine activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544528     DOI: 10.1080/15257771003730078

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  6 in total

1.  Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.

Authors:  Keishi Yoshida; Atsushi Fujita; Hidehiko Narazaki; Takeshi Asano; Yasuhiko Itoh
Journal:  Cancer Chemother Pharmacol       Date:  2021-11-26       Impact factor: 3.333

2.  DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.

Authors:  Myrna Candelaria; Erick de la Cruz-Hernandez; Lucia Taja-Chayeb; Enrique Perez-Cardenas; Catalina Trejo-Becerril; Aurora Gonzalez-Fierro; Alma Chavez-Blanco; Ernesto Soto-Reyes; Guadalupe Dominguez; Jaenai E Trujillo; Jose Diaz-Chavez; Alfonso Duenas-Gonzalez
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

3.  A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.

Authors:  Weili Sun; Timothy Triche; Jemily Malvar; Paul Gaynon; Richard Sposto; Xiaojing Yang; Henrique Bittencourt; Andrew E Place; Yoav Messinger; Chris Fraser; Luciano Dalla-Pozza; Bodour Salhia; Peter Jones; Alan S Wayne; Lia Gore; Todd M Cooper; Gangning Liang
Journal:  Blood       Date:  2018-01-16       Impact factor: 25.476

4.  MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients.

Authors:  Neha S Bhise; Lata Chauhan; Miyoung Shin; Xueyuan Cao; Stanley Pounds; Vishal Lamba; Jatinder K Lamba
Journal:  Front Pharmacol       Date:  2016-01-28       Impact factor: 5.810

5.  Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.

Authors:  Meixian Huang; Takeshi Inukai; Kunio Miyake; Yoichi Tanaka; Keiko Kagami; Masako Abe; Hiroaki Goto; Masayoshi Minegishi; Shotaro Iwamoto; Eiji Sugihara; Atsushi Watanabe; Shinpei Somazu; Tamao Shinohara; Hiroko Oshiro; Koshi Akahane; Kumiko Goi; Kanji Sugita
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

6.  The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation.

Authors:  Amber Blaauboer; Peter M van Koetsveld; Dana A M Mustafa; Jasper Dumas; Fadime Dogan; Suzanne van Zwienen; Casper H J van Eijck; Leo J Hofland
Journal:  Biomedicines       Date:  2022-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.